Article Text

Download PDFPDF

P09.04 Oncolytic H5N1 influenza strain displays superior therapeutic properties independent of immuno-stimulatory interleukin-2 transgene expression
  1. J Kabiljo1,
  2. I Kuznetsova1,
  3. J Homola1,
  4. S Prodinger1,
  5. J Laengle1,2,
  6. M Sachet1,
  7. A Egorov3 and
  8. M Bergmann1,2
  1. 1Division of General Surgery, Department of Surgery, Comprehensive Cancer Center Vienna, Medical University of Vienna, Waehringer Guertel 18-20, A-1090 Vienna, Austria, Vienna, Austria
  2. 2Ludwig Boltzmann Institute Applied Diagnostics, Medical University of Vienna, Waehringer Guertel 18-20, 1090 Vienna, Austria, Vienna, Austria
  3. 3Research Institute of Influenza, Russian Academy of Medical Sciences, Prof. Popova Str. 15/17 196376 St. Petersburg, Russia., St. Petersburg, Russian Federation


Background Oncolytic viruses are becoming an integral part of immunological approaches to cancer treatment. Interleukin-2 (IL-2) is known to stimulate cytotoxic T-cells, and might therefore be a reasonable cargo to enhance the therapeutic effect of such viruses. However, IL-2 is also known to promote immunosuppressive regulatory T-cells (T-reg). We investigated the impact of virally expressed IL-2 on induction of regulatory T-cells. We further investigated the effect of virally expressed IL-2 on the therapeutic efficacy of influenza A H1 and H5 subtypes.

Materials and Methods Survival of B16 melanoma xenograft bearing mice upon treatment with various oncolytic influenza viruses was examined. Effect of these viruses on PBMC gathered from 4 young healthy volunteers and murine and human melanoma cell lines was examined utilizing multiple flow cytometry protocols.

Results Viral IL-2 expression did not alter viral growth and was stable up to multiple passages in cell cultures. In human PBMC viral expression of IL-2 did not enhance differentiation of T-cells into a regulatory phenotype. In a murine B16 xenograft model IL-2 expression significantly enhanced therapeutic effects of an H1 oncolytic influenza virus. Expressed within the background of H5 hemagglutinin, IL-2 did not lead to a significant enhancement of therapeutic efficacy. Interestingly, the empty influenza H5 subtype was significantly more potent in treating B16 xenograft tumors than the H1 subtype, regardless of IL-2 expression. In primary human PBMC models, the virus based on H1 hemagglutinin led to enhanced CD8 T-cell activation compared to H5. This effect was further enhanced by IL-2 expression, although all viruses led to significant activation. Surprisingly, viruses based on H1 hemagglutinin led to increased expression of the immune checkpoint PD-1. The virus based on H5 hemagglutinin did not lead to upregulation of PD-1, indicating a favorable balance between activation and exhaustion. Infection with the H5 based virus led to both enhanced apoptosis and immunogenic calreticulin exposure in human and murine melanoma cell lines compared to H1.

Conclusions IL-2 does not promote T-regs, when expressed in a viral background. H1 viruses induced PD-1 more potently than H5 viruses. The choice of viral entry protein is more relevant for the therapeutic effect of the virus, than the expression of a T-cell stimulating cytokine such as IL-2. Efficacy of oncolytic viral treatment appears to depend more on viral growth than on virally expressed T-cell promoting cargo.

Disclosure Information J. Kabiljo: None. I. Kuznetsova: None. J. Homola: None. S. Prodinger: None. J. Laengle: None. M. Sachet: None. A. Egorov: A. Employment (full or part-time); Modest; Vacthera Bio Tech GmbH. M. Bergmann: A. Employment (full or part-time); Modest; Vacthera Bio Tech GmbH.

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.